Mesenchymal Stem Cells for Idiopathic Dilated Cardiomyopathy

Learn more about:
Related Clinical Trial
Evaluation of the CIRCULATE Catheter for Transcoronary Administration of Pharmacologic and Cell-based Agents Intraventricular Stasis In Cardiovascular Disease Dilated Cardiomyopathy-Cardiac Magnetic Resonance (DCM-CMR) Ancillary Study A 10-Minute Cardiovascular Magnetic Resonance Protocol for Cardiac Disease CorCinch-HF Repair System in Patients Who Present With Symptomatic Non-Ischemic or Ischemic Dilated Cardiomyopathy Early Administration of Ivabradine in Children With Heart Failure Metabolomics and Microbiomics in Cardiovascular Diseases Mannheim TORCH-Plus is a Registry for Patients With Cardiomyopathies and Serves as Source for Cardiovascular Research Studies Risk Stratification in Children and Adolescents With Primary Cardiomyopathy Pediatric Cardiomyopathy Mutation Analysis German Centre for Cardiovascular Research Cardiomyopathy Register Hemodynamic Evaluation of Preload Responsiveness in Children by Using PiCCO An Integrative-“Omics” Study of Cardiomyopathy Patients for Diagnosis and Prognosis in China Metabolomic Study of All-age Cardiomyopathy Coronary Artery Disease and Coronary Microvascular Disease in Cardiomyopathies Registry The Genetics of Cardiomyopathy and Heart Failure Inflammation, Cardiac Sympathetic Innervation, and Arrhythmic Sudden Death Comparative Effectiveness Research to Assess the Use of Primary ProphylacTic Implantable Cardioverter Defibrillators in Europe Randomized Trial of Interventions to Improve Warfarin Adherence Testing Strategies to Improving Warfarin Adherence Prospective Study Looking at Quality of Life Measures in Non-ischaemic Cardiomyopathy After Mitral Valve Repair Left Cardiac Sympathetic Denervation for Cardiomyopathy Feasibility Pilot Study The Cardiovascular Genetic and Therapeutic Implications of Muscular Dystrophy A Randomized Trial of Carvedilol in Chronic Chagas Cardiomyopathy Role of Endothelial Function, Muscular Fitness and Metabolism in Functional Activity in Patients With Chronic Heart Failure (CHF) Echo Assessment of Intraventricular Dyssynchrony Brain Function and Perfusion in Patients With Heart Failure Molecular and Imaging Studies of Cardiovascular Health and Disease Genotype-Phenotype Associations in Pediatric Cardiomyopathy (PCM GENES) Optimizing Left Ventricular Lead To Improve Cardiac Output Using Ripple Mapping to Guide Substrate Ablation of Scar Related Ventricular Tachycardia. Long-term Evaluation of Patients Receiving Bone Marrow-derived Cell Administration for Heart Disease Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-491 Efficacy and Safety Study of Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure Harefield Recovery Protocol Study for Patients With Refractory Chronic Heart Failure ACC – Atrial Contribution to CRT Follow-up Safety Trial in Children With Chronic Heart Failure Therapy Receiving Orodispersible Minitablets of Enalapril Non-Invasive Evaluation of Myocardial Stiffness by Elastography in Pediatric Cardiology (Elasto-Pédiatrie) Manganese-Enhanced Magnetic Resonance Imaging of the Myocardium Efficacy of Implantable Cardioverter Defibrillator in Patients With Non-ischemic Systolic Heart Failure on Mortality Cardiac Biomarkers in Pediatric Cardiomyopathy (PCM Biomarkers) Arrhythmia Prediction Trial Exome Sequencing Study in Cardiomyopathy to Identify New Risk Variants A Single Ascending Dose Study Assessing the Safety, Tolerability, PK and PD of MYK-491 Exercise Stress MRI to Evaluate Aortic Function (Compliance, Distensibility, Pulse Wave Velocity) and Left Ventricular Function : Validation in Healthy Volunteers and in Selected Patients. A Pilot Study. Randomized Clinical Trial of Intravenous Infusion Umbilical Cord Mesenchymal Stem Cells on Cardiopathy Observational Trial of Cardiotoxicity in Patients Undergoing Chemotherapy. A Pivotal Trial to Establish the Efficacy and Safety of Algisyl in Patients With Moderate to Severe Heart Failure Effect of Rosuvastatin on Left Ventricular Remodeling Intraventricular Stasis in Non Ischemic Dilated Myocardiopathy Assessment of Right Ventricular Function in Advanced Heart Failure An Open Label Rollover Trial for Patients Randomized to the Control Group of Study LSH-10-001 Optimized Biventricular Pacing Allograft Recipients BiPAP for Cardiomyopathy With Central Sleep Apnea Relationship Between Abnormalities of Desmin Cytoskeleton, Mitochondrial Activity and Expression of Ubiquitin in Aspect of Pathogenesis of Heart Failure and Prognosis Effect of Aldosterone on Energy Starvation in Heart Failure Resveratrol: A Potential Anti- Remodeling Agent in Heart Failure, From Bench to Bedside Therapy With Verapamil or Carvedilol in Chronic Heart Failure Effect of Beta-blockers on Structural Remodeling and Gene Expression in the Failing Human Heart Training Study to Evaluate the Benefit of Exercise for Patients With Chronic Heart Failure Danish ICD Study in Patients With Dilated Cardiomyopathy Cardiovascular Magnetic Resonance GUIDEd Insertion of Implantable Cardiac Defibrillator in Dilated CardioMyopathy DCM Precision Medicine Study A Randomized, Controlled Study to Evaluate Algisyl-LVR™ as a Method of Left Ventricular Augmentation for Heart Failure The Genetics of Dilated Cardiomyopathy: A Quebec-Based Study Potential Role of Water-soluble Ubiquinol in Complementary Therapy for Pediatric Dilated Cardiomyopathy A Trial of Autologous Bone Marrow Derived Stem Cells in Paediatric Heart Failure Resynchronization Therapy in Young Patients With and Without CHD Withdrawal of Medication in Recovered DCM Use of Bone Marrow Derived Stem Cell and G-CSF With Circulatory Assistance in the Treatment of DCM The Influence of Atorvastatin on the Parameters of Inflammation and the Function of Left Ventricle Safety and Feasibility of Algisyl-LVR™ as a Method of Left Ventricular Restoration in Patients With DCM Undergoing Open-heart Surgery PUFAs and Left Ventricular Function in Heart Failure 18F-deoxyglucose (FDG) PET-CMD Repetitive Intramyocardial CD34+ Cell Therapy in Dilated Cardiomyopathy (REMEDIUM) Study of Qiliqiangxin Capsule to Treat Dilated Cardiomyopathy Autologous Transplantation of Bone Marrow Mononuclear Stem-Cells by Mini-Thoracotomy Combination of Olmesartan Effect on Myocardial Viability of Patients With Dilated Cardiomyopathy Mesenchymal Stem Cells for Idiopathic Dilated Cardiomyopathy Continues Positive Airway Pressure Treatment for Patients With Dilated Cardiomyopathy and Obstructive Sleep Apnea Pathophysiology of Dilated Cardiomyopathy Multicenter Exploratory Study of Accelerometry in Dilated Cardiomyopathy Transcoronary Infusion of Cardiac Progenitor Cells in Pediatric Dilated Cardiomyopathy Autologous Transplantation of Bone Marrow Mononuclear Stem-Cells for Dilated Cardiomyopathy Clinical and Genetic Examinations of Dilated Cardiomyopathy Simvastatin Therapy in Patients With Dilated Cardiomyopathy. Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy Safety and Efficacy Study of Intramyocardial Stem Cell Therapy in Patients With Dilated Cardiomyopathy Respiratory Muscles Training in Patients With Dilated Cardiomyopathy Myocardial Metabolism in Patients With Dilated Cardiomyopathy Intracoronary Autologous Mesenchymal Stem Cells Implantation in Patients With Ischemic Dilated Cardiomyopathy Orodispersible Minitablets of Enalapril in Children With Heart Failure Due to Dilated Cardiomyopathy Multicenter Study of Immunoadsorption in Dilated Cardiomyopathy Cell Therapy In Dilated Cardiomyopathy Safety and Efficacy Study of Stem Cell Transplantation to Treat Dilated Cardiomyopathy Intracoronary Infusion of Autologous Bone Marrow Cells for Treatment of Idiopathic Dilated Cardiomyopathy Infusion Intracoronary of Mononuclear Autologous Adult no Expanded Stem Cells of Bone Marrow on Functional Recovery in Patients With Idiopathic Dilated Cardiomyopathy and Heart Failure. Nesiritide – Dilated Cardiomyopathy A Study of Impact of Anemia on Morbidity and Mortality in Children With Dilated Cardiomyopathy Defining the Role of Insulin Resistance in ‘Idiopathic’ Dilated Cardiomyopathy Use of Ixmyelocel-T (Formerly Cardiac Repair Cell [CRC] Treatment) in Patients With Heart Failure Due to Dilated Cardiomyopathy (IMPACT-DCM) Use of Ixmyelocel-T (Formerly Catheter-based Cardiac Repair Cell [CRC]) Treatment in Patients With Heart Failure Due to Dilated Cardiomyopathy A Pilot Trial of Ranolazine to Treat Patients With Dilated Cardiomyopathy Coenzyme Q10 Supplementation in Children With Idiopathic Dilated Cardiomyopathy Supramaximal Titrated Inhibition of RAAS in Dilated Cardiomyopathy Intramuscular Injection of Mesenchymal Stem Cell for Treatment of Children With Idiopathic Dilated Cardiomyopathy Honey in Idiopathic Dilated Cardiomyopathy A Clinical Study of Immunoadsorption Therapy for Dilated Cardiomyopathy

Brief Title

Mesenchymal Stem Cells for Idiopathic Dilated Cardiomyopathy

Official Title

Phase I/II Randomized Clinical Trial to Assess the Safety and Feasibility of Transendocardial Injection of Bone Marrow Autologous Mesenchymal Stem Cells in Patients With Idiopathic Dilated Cardiomyopathy.

Brief Summary

      The purpose of this study is to assess the safety, the feasibility and the efficacy of
      transendocardial injection of bone marrow-derived mesenchymal stem cells (MSCs) in patients
      with dilated idiopathic cardiomyopathy.

Detailed Description

      Chronic congestive heart failure (CHF) is a public health problem that entails high rates of
      morbidity and mortality, and enormous costs for health systems worldwide. In the United
      States there are 5 million people living with CHF, and each year 60.000 people reach terminal
      phases of the disease, with mortality rates of 70-80% at two years. Although the first cause
      of CHF in developed countries is atherosclerotic coronary artery disease (CAD), dilated
      idiopathic cardiomyopathy (DCM) represents almost half of the cases of newly diagnosed CHF.
      Treatment of CHF includes pharmacological and non-pharmacological strategies, including
      implantable cardioverter defibrillators, cardiac resynchronization therapy and heart
      transplantation. Despite all these advances, CHF prognosis remains poor. Cardiac stem cell
      therapy emerged more than ten years ago as a new hope for CHF patients.

      Although the most extensive evidence of the benefits of stem cell therapy for cardiovascular
      diseases refers to ischemic heart disease (CAD), initial experiences with stem cells for
      other conditions such as DCM are encouraging.

      This randomized clinical trial will include 70 patients with DCM, left ventricular ejection
      fraction (LVEF) between 20% and 45%, and who are symptomatic in New York Heart Association
      (NYHA) functional class II-III/IV. In a first-in-man pilot phase, 10 patients will be treated
      with transendocardial injections of bone marrow-derived MSCs after cardiac catheterization
      and NOGA XPTM mapping of the left ventricle. A Data and Safety Monitoring Board (DSMB) will
      analyse the safety and feasibility of this first phase of the trial, and then 60 patients
      more will be randomized to receive MSCs or placebo (ratio 3:1).

      Primary objectives include safety and feasibility variables, and secondary objectives include
      efficacy variables. All patients will be studied with a complete cardiac imaging protocol
      that includes: electrocardiography, echocardiography, treadmill tests with oxygen
      consumption, holter, laboratory analyses, magnetic resonance imaging (MRI), single photon
      emission computed tomography (SPECT), electromechanical mapping (NOGA XPTM) and quality of
      life questionnaires.

Study Phase

Phase 1/Phase 2

Study Type


Primary Outcome

Major adverse cardiac adverse events. SAEs and AEs.

Secondary Outcome

 NYHA Functional Class


Primary Idiopathic Dilated Cardiomyopathy


bone marrow-derived MSCs injection

Study Arms / Comparison Groups

 placebo comparator
Description:  transendocardial injection of placebo solution


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

March 2013

Completion Date

March 2018

Primary Completion Date

March 2018

Eligibility Criteria

        Inclusion Criteria:

          -  II-III NYHA functional class, under optimal medical therapy.

          -  LVEF ≥ 20% and ≤ 45% by echocardiography, SPECT or left ventriculogram one month prior
             to enrollment.

          -  Anterior wall thickness ≥ 8 mm by echocardiography or MRI one month prior to

          -  Idiopathic DCM diagnosis (having excluded CAD, valvular heart disease, cardiac toxic
             drugs, tachyarrhythmias, metabolic diseases, systemic diseases, infectious diseases)
             six months prior to enrollment.

          -  Patients rejected for heart transplantation should have been discussed in the Heart
             Team at their respective centres, and a document stating the reason for exclusion will
             be kept in the medical record.

          -  Able to exercise on a treadmill, MVO2 between ≥ 12 and ≤ 21 ml/Kg/min.

          -  Hemodynamic stability (blood pressure > 100/40 mmHg, heart rate < 110 bpm and oxygen
             saturation > 95%).

          -  Negative pregnancy test in women.

          -  Signed informed consent

        Exclusion Criteria:

          -  Evidence of secondary dilated cardiomyopathy causes: CAD, valvular heart disease,
             cardiac toxic drugs, tachyarrhythmias, metabolic diseases, systemic diseases,
             infectious diseases, myocarditis or postpartum ventricular dysfunction.

          -  Permanent atrial fibrillation.

          -  Candidates for ICD or CRT devices. Patients with theses devices can be enrolled if the
             device has been implanted at least 6 months before inclusion, and only if no-response
             has been observed to CRT.

          -  Candidates for heart transplantation if surgery is anticipated in the next 2 years.

          -  Left ventricular thrombus by echocardiography, MRI or left ventriculogram.

          -  Peripheral artery disease that precludes cardiac catheterization with 8 Fr sheaths. .

          -  Anterior wall thickness < 8 mm by echocardiography or MRI one month prior to

          -  Chronic renal failure (creatinine > 2,5 mg/dL).

          -  I or IV NYHA functional class. Cardiogenic shock is defined as systolic blood pressure
             < 90 mmHg with no response to fluids, or < 100 mmHg with inotropes and without

          -  Previous history of drug abuse (alcohol, etc…).

          -  Acute or chronic infectious disease (including B/C hepatitis and HIV).

          -  Pregnancy or child-bearing period.

          -  MRI contraindications: pacemakers, ICD, metalic prosthesis, etc.

          -  Bleeding or coagulation disorders (INR > 2 without anticoagulation treatment).

          -  Cancer history 5 years prior to enrollment.

          -  Life expectancy less than 1 year.

          -  Any disease or condition that the investigator finds decisive for exclusion




18 Years - 80 Years

Accepts Healthy Volunteers



Francisco Fernandez Aviles, PhD, 034 91 426 5882, [email protected]

Location Countries


Location Countries


Administrative Informations



Organization ID


Secondary IDs


Responsible Party


Study Sponsor

Hospital General Universitario Gregorio Marañon


 Ministerio de Sanidad, Servicios Sociales e Igualdad

Study Sponsor

Francisco Fernandez Aviles, PhD, Study Chair, Hospital General Universitario Gregorio Marañón

Verification Date

November 2016